Cemiplimab
Treatment for Non-melanoma skin cancer (squamous-cell carcinoma)
Typical Dosage: 350 mg IV every 3 weeks
Effectiveness
88%
Safety Score
40%
Clinical Trials
7
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
350 mg IV every 3 weeks
Time to Effect
2-4 months
Treatment Duration
Months to years
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$153,000
Monitoring:$3,000
Side Effect Mgmt:$7,000
Total Annual:$163,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$362,222
Cost per Remission
$905,556
Comparison vs Systemic Chemotherapy
Cost Difference
+$100,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Cemiplimab Outcomes
for Non-melanoma skin cancer (squamous-cell carcinoma)
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+45%
Remission Rate
+18%
Common Side Effects
Fatigue
+40%
Musculoskeletal pain
+30%
Rash
+25%
Diarrhea
+20%
Immune-related adverse events
+10%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
4 active trials recruiting for Cemiplimab in Non-melanoma skin cancer (squamous-cell carcinoma)
Deep sequencIng in Cutaneous Squamous CEll caRciNomas
NCT05878288ACTIVE NOT RECRUITINGPHASE2
11 participants
INTERVENTIONAL
Melbourne, Australia
Started: May 26, 2023
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410RECRUITINGPHASE3
369 participants
INTERVENTIONAL
Phoenix, United States +48 more
Started: Jan 2, 2025
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
NCT05574101ACTIVE NOT RECRUITINGPHASE2
34 participants
INTERVENTIONAL
Aurora, United States +12 more
Started: Oct 6, 2022
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029RECRUITINGPHASE1
168 participants
INTERVENTIONAL
Los Angeles, United States +15 more
Started: Oct 13, 2023
Completed Clinical Trials
1 completed trial for Cemiplimab in Non-melanoma skin cancer (squamous-cell carcinoma)
Comparative Efficacy of Cemiplimab to Historical Standard of Care in France
NCT05302297COMPLETED
305 participants
OBSERVATIONAL
France, France
Started: Jan 17, 2022